Evercore ISI raised the firm’s price target on BridgeBio (BBIO) to $50 from $45 and keeps an Outperform rating on the shares ...

As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has ...

Tax-loss selling candidates such as Nike, could surprise investors with big gains in 2025, say Evercore strategists.

Evercore ISI analyst Gavin Clark-Gartner maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report) on December 20 and set a ...

We recently published a list of 10 Buzzing AI Stocks on Latest News and Ratings. In this article, we are going to take a look ...

Keefe, Bruyette & Woods analyst Aidan Hall upgraded the rating for Evercore Inc. EVR from Market Perform to Outperform and ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $307.2, a high ...

Keefe Bruyette upgraded Evercore (EVR) to Outperform from Market Perform with a price target of $339, up from $269. The firm says that despite ...

ChargePoint's stock has plunged since its SPAC-backed debut. It faces tough macro and competitive headwinds. It could trade at a discount valuation for the foreseeable future. But today, it trades at ...

It's been a bit of an odd year for Evercore Heroes: Ascension. To catch you up, the game entered 2024 as kind of a mash-up ...

Jonathan Chappell, Evercore ISI Senior Managing Director, joins 'Closing Bell: Overtime' to discuss FedEx earnings, company ...

For those who were unable to attend the recent Boston Private Equity Network (BPEN) panel and webinar on Continuation Funds – Moderated by ...